Physician profile
Robert B Legler
NPI 1811128598
$3,250.89
in general payments reported to CMS, 2019-2025
38 companies · $749 in 2025
The $749 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $355 · 2021: $624 · 2022: $485 · 2023: $273 · 2024: $258 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.06 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $419.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $324.04 | 2021-2025 | |
| Lilly USA, LLC | $245.70 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $215.69 | 2019-2023 | |
| Amgen INC. | $187.76 | 2019-2021 | |
| Novo Nordisk INC | $167.28 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.72 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $146.29 | 2019-2023 | |
| Glaxosmithkline, LLC. | $145.40 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.00 | 2019-2025 | Jardiance |
| Lnhc, INC | $130.00 | 2025 | Zelsuvmi |
| Merck Sharp & Dohme LLC | $94.29 | 2020-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $73.77 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.40 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $69.26 | 2023-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Legler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.